BlossomHill Therapeutics, Inc. Common Stock (BLSM) — Cash Flow-to-Debt Ratio
BlossomHill Therapeutics, Inc. Common Stock (BLSM) has a Cash Flow-to-Debt Ratio of -0.07x as of March 2026, meaning its operating cash flow of $-20.94 Million could theoretically repay 0% of its total liabilities ($295.53 Million) in one year. See BLSM financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BlossomHill Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio (2024–2025)
Historical debt coverage capacity for BlossomHill Therapeutics, Inc. Common Stock across 2 annual periods. For the full cash flow conversion analysis, see BlossomHill Therapeutics, Inc. Common St operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for BlossomHill Therapeutics, Inc. Common Stock (2024–2025)
Year-by-year debt coverage analysis for BlossomHill Therapeutics, Inc. Common Stock.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.16x | $-46.92 Million | $294.70 Million | ▲ +8.9% |
| 2024 | -0.17x | $-31.42 Million | $179.66 Million | — |